Protalix BioTherapeutics Inc. [PLX] stock prices are up 5.84% to $1.63 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The PLX shares have gain 13.99% over the last week, with a monthly amount glided 9.40%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 23, February 2024, Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference. In a post published today on Yahoo Finance, Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET.
From an analyst’s perspective:
Protalix BioTherapeutics Inc. [AMEX: PLX] stock has seen the most recent analyst activity on June 08, 2020, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $11 from $3. Previously, Rodman & Renshaw reaffirmed its Buy rating on April 17, 2017, and elevated its price target to $5. On April 04, 2016, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $3.50 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $2.60 on April 23, 2015. R. F. Lafferty reiterated its recommendation of a Buy and reduced its price target to $5 on November 12, 2014. R. F. Lafferty started tracking with a Buy rating for this stock on January 24, 2014, and assigned it a price target of $8. In a note dated May 02, 2012, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $9 to $11.
The stock price of Protalix BioTherapeutics Inc. [PLX] has been fluctuating between $1.21 and $3.55 over the past year. Protalix BioTherapeutics Inc. [AMEX: PLX] shares were valued at $1.63 at the most recent close of the market.
Analyzing the PLX fundamentals
The Protalix BioTherapeutics Inc. [AMEX:PLX] reported sales of 63.62M for trailing twelve months, representing a drop of -27.06%. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.63 and Total Capital is 0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5733 points at the first support level, and at 1.5167 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6733, and for the 2nd resistance point, it is at 1.7167.
Protalix BioTherapeutics Inc. [PLX] reported earnings per share of -$0.04 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.07/share, meaning a difference of $0.03 and a surprise factor of 42.90%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $0.21 per share as compared to estimates of -$0.04 per share, a difference of $0.25 representing a surprise of 625.00%.
Ratios To Look Out For
It’s worth pointing out that Protalix BioTherapeutics Inc. [AMEX:PLX]’s Current Ratio is 1.67. On the other hand, the Quick Ratio is 1.18, and the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 1.87, the price to book ratio is 3.11 and price to earnings (TTM) ratio is 39.85.
Transactions by insiders
Recent insider trading involved Bashan Dror, PRESIDENT AND CEO, that happened on Oct 19 when 64516.0 shares were purchased.
